Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 2/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735305 | 0.93 | GPR119 (0.48) | F10GPR119CETPALK | |
| SCHEMBL6188847 | 0.90 | GPR119 (0.53) | F10GPR119CETPALK | |
| SCHEMBL6735302 | 0.87 | GPR119 (0.48) | F10GPR119CETPALK | |
| SCHEMBL6189509 | 0.86 | F10 (0.49) | F10GPR119CETPALKKDM4E | |
| SCHEMBL6191546 | 0.84 | F10 (0.50) | F10GPR119CETPALK | |
| SCHEMBL6187947 | 0.83 | F10 (0.62) | F10GPR119CETP | |
| SCHEMBL6190950 | 0.79 | GPR119 (0.56) | F10GPR119CETPALK | |
| SCHEMBL6191999 | 0.77 | GPR119 (0.53) | F10GPR119CETPALK | |
| SCHEMBL6192378 | 0.76 | F10 (0.55) | F10GPR119CETPNOD2NOD1 | |
| SCHEMBL6192383 | 0.76 | F10 (0.55) | F10GPR119CETPNOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | F10 16/4885GPR119 2900/4885CETP 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.